Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review

Figure S1. PRISMA Flow Diagram, Large B-Cell Lymphoma (LBCL)



*PICOS - population, intervention, comparator, outcomes, and study design

Figure S2. MAIC of experimental CAR T-cells and Yescarta regarding PFS among patients who received infusion. Kaplan Meier survival curves. Hazard Ratios and 95% Confidence Intervals computed through Cox Proportional Hazards Models.



2021, Vol. 12, No. 4, Article 18 Supplemental DOI: https://doi.org/10.24926/iip.v12i4.4345

0.1 D. Modified co-stimulatory domain for reduced toxicity: 0.8 PFS probability 0.6 Hu19.CD8.28Z 4.0 0.2 HR=2.00(1.01-3.96) 0.0 5 10 15 0 1.0 CD19. BBz.86 0.8 PFS probability 0.6 0.4 0.2 HR=1.67 (0.90-3.09) 0.0 5 10 0 1.0 0.8 PFS probability 0.6 4.0 0.2 HR=1.04(0.52-2.06) 0.0 10 5 1.0 0.8 PFS probability 0.6 4.0 0.2 HR=0.47(0.18-1.28) 0.0

Sefore MAIC (n=19 After MAIC (ESS=17) ZUMA1 (n=100) 20 25 30 35 Before MAIC (n=21) After MAIC (ESS=20) ZUMA1 (n=100) 15 20 25 Before MAIC (n=14) After MAIC (ESS=13) ZUMA1 (n=100) 15 20 25 30 Before MAIC (n=24) After MAIC (ESS=11) ZUMA1 (n=100) 10 15 20 25 0 5

E. Alternative target antigen

CD20. 4-1BBζ

F. Alternative co-stimulatory domain

CD19. 4-1BBζ